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John Koreth,1 Melinda Biernacki,2 Julie Aldridge,3 Haesook T. Kim,3 Edwin P. Alyea, III,1
Philippe Armand,1 Corey Cutler,1 Vincent T. Ho,1
Catherine J. Wu,1 Joseph H. Antin,1 Robert J. Soiffer1Engraftment syndrome (ES), typically characterized by noninfectious fever, rash, and/or noncardiogenic pul-
monary edema, is a complication of autologous and allogeneic hematopoietic stem cell transplantation
(HSCT). There are no data on ES after syngeneic HSCT. We retrospectively analyzed syngeneic HSCTout-
comes and determined ES incidence, risk factors, and prognostic impact. Thirty-two adult patients with a me-
dian age of 46 years (range: 22-60) underwent syngeneic HSCTat our institution between July 1986 and April
2009, primarily for hematologic malignancies (65% lymphoid-including 15% plasma cell; 31% myeloid). The
median duration of follow-up was 6.1 years (range: 3.7 months to 18.1 years). Five-year progression-free
and overall survival (PFS, OS) was 52% and 67%, respectively. Five-year overall cumulative incidence of re-
lapse and nonrelapse mortality (NRM) was 37.6% and 10.2%, respectively; with increased relapse incidence
of 76.3% in myeloid disease (P5.002). Fifteen patients (47%) met diagnostic criteria for ES, 10 (67%) of whom
received systemic steroids. Five-year PFS was 47% in patients with ES versus 56% in those without (P5 .37).
Five-year OS was 63% with ES versus 71% without (P5.80). Five-year cumulative incidence of NRMwas 21%
with ES versus 0%without (P5.06). Five-year cumulative incidence of relapse was 32%with ES and 44%with-
out (P5 .68). Older age (P5 .05) and possibly total body irradiation–based conditioning (P5 .09) were risk
factors for developing ES. In multivariable Cox models only diagnosis (myeloid disease) impaired OS and PFS.
In summary, we document a high incidence of ES after syngeneic HSCT. The trend of increased NRM after ES
requires reevaluation in a larger syngeneic HSCT cohort.
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Engraftment syndrome (ES) is a febrile syndrome
occurring during neutrophil recovery following hema-
topoietic stemcell transplantation (HSCT). It is charac-
terized clinically by noninfectious fever in conjunction
with clinical findings such as skin rash, hypoxia, and1Division of Hematologic Malignancies, Dana Farber
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6/j.bbmt.2010.09.013pulmonary infiltrates, fluid retention and weight gain,
organ dysfunction, diarrhea, or encephalopathy in
the peri-engraftment period [1-3]. Although described
over 15 years ago, ES remains a relatively poorly
understood complicationofHSCT[1]. Its pathogenesis
is thought to involve the release of pro-inflammatory
cytokines, systemic endothelial damage, aswell as prod-
ucts of neutrophil degranulation and oxidative metabo-
lism [2,4]. ES incidence ranges between 7% and 59% in
various reports, in part owing to different diagnostic
criteria [1,5]. The diagnostic criteria for ES include
those proposed by Spitzer and those by Maiolino et al.
[2,3]. The Spitzer criteria are considered more
stringent [6,7].
ES is an important diagnosis to make for patients
experiencing febrile syndromes during the peri-
engraftment period, because it responds dramatically
to steroids when administered in a timely fashion and
at adequate dose. However, if treatment is delayed or
inadequate, ESmay progress to irreversiblemultiorgan421
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allogeneic adult donor and umbilical cord blood
donor transplantation, but is best described after
autologous HSCT. There are no reports on ES in
the context of syngeneic HSCT. However, cases of
‘‘syngeneic graft-versus-host disease’’ (GVHD) have
been described (summarized by Latif et al. [8]) that
may represent overlap with ES.
We undertook a retrospective study of syngeneic
HSCT outcomes, with a focus on ES incidence, risk
factors, and its survival impact on adult patients treated
at the Dana-Farber Cancer Institute.PATIENTS AND METHODS
Patients
Between July 1986 and April 2009, 32 myeloabla-
tive syngeneic donor transplants were performed in
adult patients aged#60 years at theDana-Farber Can-
cer Institute. All had provided informed consent at the
time of transplant, including consent for data analysis.
Two authors (J.K., M.B.) reviewed the inpatient
medical records of all syngeneic transplants included in
the study. All patients received high-dose conditioning
chemotherapy utilizing standard regimens. These in-
cluded: cyclophosphamide plus total-body irradiation
(TBI) (18 patients); busulfan plus cyclophosphamide (5
patients); cyclophosphamide, carmustine plus etoposide
(5 patients); melphalan alone (3 patients); cyclophospha-
mide alone (1 patient). No GVHD prophylaxis, T cell
depletion, or preemptive or prophylactic donor lympho-
cyte infusions were given. HSCT supportive care, in-
cluding use of growth factors, was as per institutional
standard at the time.
Syngeneic donor typingmethodologies varied over
the time period of this report. In brief, through the
mid-1990s, HLA Class I typing was performed by se-
rologic methods only. Starting in 1996, confirmatory
HLA Class I typing was done by SSP molecular tech-
niques. HLA Class II typing was also by serology until
the early 1990s, when it was replaced by molecular
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) and SSP techniques.
Currently, syngeneic twin status is determined by
STR genotyping using the ABI Profile Plus Kit
Human Identity markers. Concordance at all 9 STR
loci plus the amelogenin locus indicates that the prob-
ability of being identical twins is .99.9%.
Donor syngeneic hematopoietic stem cells were
collected from bone marrow (16 patients) or
granulocyte-colony stimulating factor (G-CSF) mobi-
lized peripheral blood (15 patients). One patient re-
ceived both marrow and peripheral blood stem cells.
Neutrophil engraftment was assessed by the days to
absolute neutrophil count (ANC) $500/mL  2 days.
Comorbidity was determined per the HCT-CI score[9]. ES diagnosis was as per Spitzer, and was based
on major and minor criteria [2]. Major criteria com-
prised fever $38.3C with no infectious etiology; er-
ythodermatous rash involving .25% of body surface
area; and noncardiogenic pulmonary edema, with hyp-
oxia and diffuse pulmonary infiltrates. Minor criteria
comprised hepatic dysfunction with total bilirubin
$2 mg/dL or doubling of serum transaminase levels;
doubling of serum creatinine; weight gain $2.5%
over baseline; or transient unexplained encephalopa-
thy. To document ES, 3 major criteria or 2 major
and 1 minor criteria are required within 96 hours of
neutrophil engraftment. The Spitzer criteria were
modified to broaden the time period around neutro-
phil recovery, as is favored by Dispenzieri et al. [6]
and Carreras et al., to engraftment 67 days [7].
Statistical Analysis
Descriptive statistics were used to summarize pa-
tient characteristics. The Wilcoxon rank sum test,
chi-square test, or Fisher exact test was used for 2 sam-
ple comparisons. All tests were 2-sided. Cumulative
incidence curves for relapse and nonrelapse mortality
(NRM) were constructed reflecting time to relapse
and time to nonrelapse death as competing risks.
The difference between cumulative incidence curves
in the presence of a competing risk was tested using
the Gray method [10]. Time to relapse and time to
nonrelapse death were measured from the date of
stem cell infusion. Patients who were alive without re-
lapse were censored at the time last seen alive. Overall
survival (OS) and progression-free survival (PFS) were
calculated using the Kaplan-Meier method. OS was
defined as the time from stem cell infusion to death
from any cause. PFS was defined as the time from
stem cell infusion to relapse, disease progression, or
death from any cause. The log-rank test was used for
the comparisons of Kaplan-Meier curves. Prognostic
factors for OS and PFS were examined in Cox propor-
tional hazards models [11].RESULTS
Patient, Donor, and Transplant Characteristics
Clinical characteristics of the 32 patients in this study
are shown in Table 1. The median patient age was 46
years (range: 22-60). Median follow-up time among
survivors was 6.1 years (range: 3.7 months to 18.1 years)
post-HSCT.Therewere 15male and 17 female patients.
The principal diagnoses were heterogeneous, as indi-
cated in Table 1. Twelve percent had low-risk disease
(ie, acute leukemia in first complete remission [CR1],
myelodysplastic syndrome [MDS] with refractory ane-
mia [RA] or refractory anemia and ring sideroblasts
[RARS], chronic myeloid leukemia [CML] in first
chronic phase [CP1], lymphoma in CR1). The median
Table 1. Characteristics of Patients Undergoing Syngeneic HSCTwith and without Engraftment Syndrome (ES)
N No % N ES %
ES
P-Value
Total 17 100 15 100
Age
<50 15 88 8 53 .05
$50 2 12 7 47
Median (range) 44 (22-55) 48 (25-60) .12
Gender (male) 7 41 8 53 .72
Diagnosis
ALL — — 1 7
AML 2 12 1 7
Anemia/red cell disorder — — 1 7 1
CML 2 12 — —
MDS 2 12 3 20
Hodgkin Disease — — 2 13
MM/plasma cell disorder 4 24 1 7
NHL 7 41 6 40
Diagnosis (subcategorized) —
Lymphoid 11 65 10 67
Myeloid 6 35 4 27
Other — — 1 7
Cell source .85
Bone Marrow 9 53 7 47
Peripheral blood stem cells 7 41 8 53
Both 1 6 — —
HCT-CI Comorbidity Score
Low: 0 9 53 4 27
Medium: 1-2 2 12 8 53
High: $3 6 35 3 20
Median (range) 0 (0, 7) 1 (0, 4)
Steroid therapy <.0001
No 17 100 5 33
Yes — — 10 67
Year of transplant 1.00
<2002 10 59 8 53
$2002 7 41 7 47
Disease risk status .60
High 14 82 14 93
Low* 3 18 1 7
Conditioning .09
TBI 7 41 11 73
non-TBI 10 59 4 27
Median time to engraftment (range) 11.5 (5-29) 12 (9-22)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, mul-
tiple myeloma; NHL, non-Hodgkin lymphoma; ES, engraftment syndrome; TBI, total-body irradiation; HSCT, hematopoietic stem cell transplantation.
*AML/ALL in first complete remission (CR1), CML in chronic phase (CP1), MDSwith retinoic acid (RA) or retinoic acid receptors (RARS), lymphoma inCR1.
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There were 15 patients with ES (median age: 48;
range: 25-60) and 17 patients without ES (median
age: 44; range: 22-55). Of the patients with ES, 10
(67%) were prospectively diagnosed during HSCT,
and received a short course of systemic steroids with
prompt resolution of symptoms in all but 1 case. The
median follow-up time among survivors with andwith-
out ESwas 6.1 years (range: 6.3months to 18 years) and
5.2 years (range: 3.7months to 10.8 years), respectively.
ES and non-ES groups did not differ significantly with
regard to covariates of sex donor stem cell source (pe-
ripheral blood stem cell [PBSC] versus bone marrow),
diagnosis (myeloid versus lymphoid); disease risk at
transplant (low versus high risk), time to neutrophil en-
graftment, HCT-CI comorbidity score, and year of
transplant (\2002 versus $2002); but did differ withregard to patient age (\50 versus $50 years) (P 5 .05),
and possibly with regard to conditioning regiment (TBI
versus non-TBI) (P5 .09) (Table 1).
Survival Outcomes
For the syngeneic HSCT cohort, 5-year PFS was
52% (95% confidence interval, 32-69); and OS was
67% (95% CI, 45-81). The 5-year overall cumulative
incidence of relapse and NRM was 37.6% and
10.2%, respectively (Figure 1A). When stratified by
diagnosis, relapse risk, but not NRM, was increased
in patients with myeloid disorders versus those with
lymphoid (including plasma cell) disorders, at 76.3%
versus 17% (P 5 .002) and 10% versus 10.4%
(P 5 .95), respectively (Figure 1B).
Comparing ES patients versus those without ES,
5-year PFS was 47% (95% CI, 20-71) versus 56%
(95% CI, 26-78; P 5 .37) (Figure 1C). Five-year OS
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Figure 1. (A) Cumulative incidence of relapse and NRM as competing risks—overall. (B) Cumulative incidence of relapse and NRM as competing
risks—by diagnosis (n 5 31). (C) Progression-free survival—by ES cohort. (D) Overall survival—by ES cohort. (E) Cumulative incidence of relapse
and NRM as competing risks—by ES cohort.
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CI, 32-83) versus 71% (95% CI, 39-88; P 5 .80), re-
spectively (Figure 1D). Five-year cumulative incidence
ofNRMwas 21% for patients with ES versus 0%with-
out ES (P 5 .06). Five-year cumulative incidence ofrelapse was 32% for patients with ES versus 44%with-
out ES (P 5 .68) (Figure 1E). Similar 5-year PFS and
OS outcomes were noted when the ES cohort was
restricted to the 10 patients treated with steroids
(P 5 .14; P 5 .52, respectively).
Table 2. Multivariable Cox Models—Adjusted Model (Age, Sex and Year of Transplant Are Adjusted for Each Model*)
Model OS PFS
Variable (+ Age + Gender + Transplant) n HR 95% CI P HR 95% CI P
Engraftment syndrome versus none 32 1.16 0.33-4.03 .81 1.77 0.58-5.46 .32
Disease risk status, high versus low 32 1.07 0.12-9.42 .95 1.66 0.24-11.72 .61
Time to engraftment (continuous) 32 0.98 0.87-1.11 .74 0.97 0.86-1.10 .62
Diagnosis, myeloid versus lymphoid† 31 8.47 1.73-41.58 .009 4.83 1.33-17.53 .017
HCT-CI, high versus low/medium 32 0.54 0.11-2.72 .45 0.58 0.14-2.50 .47
Conditioning, TBI versus no TBI 32 1.21 0.28-5.19 .80 0.77 0.20-2.97 .70
OS indicates overall survival; PFS, progerssion-free survival; HR, hazard ratio; CI, confidence interval; TBI, total-body irridiation.
Note: Wald test P value for the coefficient.
*For each model, age, sex and year of transplant were nonsignificant.
†One patient with diagnosis of ‘‘other’’ was not included in this model.
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We evaluated the impact of ES in a multivariable
Cox model of survival outcomes (PFS, OS) (Table
2). Because of the limited sample size, patient age (con-
tinuous), sex and year of transplant (\2002 versus
$2002) were included in every model and comorbidity
score (HCT-CI: high versus moderate/low), diagnosis
(myeloid versus lymphoid), disease-risk (high versus
low) time to engraftment (continuous), conditioning
regimen (TBI versus non-TBI), or ES (present versus
absent) was added separately. Survival outcomes were
significantly impaired in patients with myeloid disor-
ders, with PFS and OS hazard ratios of 4.83 (95%
CI, 1.33-17.53, P 5 .017) and 8.47 (95% CI,
1.73-41.58, P 5 .009), respectively. No other covari-
ate, including ES, was associated with OS and PFS
endpoints.
DISCUSSION
ES, a complication of HSCT, classically comprises
a maculopapular skin rash and noninfectious fever,
with or without fluid retention and weight gain, hyp-
oxia with noncardiogenic pulmonary edema, among
others. ES is best described after autologous HSCT,
but also reported in the allogeneic UCB and adult do-
nor context. However, ES incidence, risk factors, and
impact on survival outcomes needs to be more fully
characterized.
Our understanding of the pathogenesis of ES
remains limited, even in the context of autologous
HSCT. Various risk factors for the development of
ES in patientswith hematologic disease undergoing au-
tologousHSCT have been described, including female
sex [5], prior chemotherapy [12], increased number of
infused hematopoietic cells [5,13], peripheral blood as
a source of stem cells [1,5], accelerated neutrophil
reconstitution [5,14], and use of G-CSF and
granulocyte macrophage-colony stimulating factor
(GM-CSF) [15]. Most ES risk factors have not been re-
producible across studies. With regard to outcome,
most studies have not reported impaired survival in pa-
tients with ES, although there are exceptions [16].There is no information on ES in the context of
syngeneic HSCT. Although rare, syngeneic transplan-
tation represents an opportunity to better understand
ES because there are fewer clinical variables in synge-
neic HSCT. For instance, unlike autologous HSCT,
variables of tumor contamination, prior cancer chemo-
therapy, and impact of chemotherapy-based stem cell
mobilization are nonrelevant for syngeneic donor
cells. Also, unlike allogeneicHSCT, variables of donor
sex and age, HLA-match, ABO-match, GVHD pro-
phylaxis, and incidence are not relevant in syngeneic
HSCT.
This is the first report on ES in the context of
syngeneic HSCT. It comprises a sizeable cohort of 32
transplants undertaken in a single institution with
extended follow-up over the past 23 years. Previously,
individual case reports have documented ‘‘syngeneic
GVHD’’ over the years, summarized by Latif et al.
[8], who identified a total 19 cases in the medical liter-
ature from 1979 to 2003. ‘‘Syngneic GVHD’’ has some
overlapping features with ES, for instance, maculopap-
ular skin rashwas described in all cases, typically during
the peri-engraftment period (7-21 days posttrans-
plant); and for the 50% who received it, therapy typ-
ically comprised steroids (6cyclosporine). However,
the overlap with ES remains uncertain, given other
discordant features in ‘‘syngeneic GVHD,’’ such as
lack of reported fever; and the fact that some patients
had recurrent symptoms at up to 303 days posttrans-
plant, despite extended therapy.
In our syngeneic HSCT cohort, ES is frequent, in-
volving 47% of patients. Of these, two-thirds were
prospectively diagnosed and received steroid therapy,
as is appropriate. However, one-third of ES cases
were not diagnosed in a timely fashion, highlighting
the clinical relevance of considering ES in the differen-
tial diagnosis of febrile syndromes after syngeneic
HSCT. The steroid-treated patients experienced
prompt resolution of ES symptoms (with 1 exception,
who died of respiratory failure), and experienced no
GVHD flare after rapid taper of steroids, confirming
the DNA-identical nature of the transplant. Three
ES patients had NRM. As previously mentioned, 1
426 Biol Blood Marrow Transplant 17:421-428, 2011J. Koreth et al.patient died on day 141 post-HSCT, of progressive
acute respiratory distress syndrome (ARDS) in the
context of ES, despite treatment with steroids. The
second ES patient (also prospectively treated with ste-
roids) died of parainfluenza pneumonitis and ARDS at
4 months post-HSCT, and the third ES patient (not
prospectively treated with steroids), died of congestive
heart failure (CHF) with dilated cardiomyopathy, asci-
tes, and portal hypertension of unclear etiology at15
months post-HSCT.
Our study has limitations. As a retrospective sin-
gle-institution analysis it is subject to bias, for instance,
in patient referral, selection for HSCT, and possibly in
the determination of complex clinical events from the
medical record. Additionally, given the long time pe-
riod involved in accruing patients receiving this rare
therapeutic modality, secular changes in clinical prac-
tice involvingHSCT selection,methodology, and sup-
portive care impact this analysis. For instance,
variables such as CD341 stem cell dose and growth
factor use were not systematically documented during
the earlier time periods of this analysis (ie, prior to the
mid–late 1990s). Furthermore, although this 32-pa-
tient cohort is large for a rare therapeutic modality
like syngeneic HSCT, it does limit our ability to
undertake detailed statistical analyses and confirm
clinically meaningful associations.
Nonetheless, some notable findings have emerged.
In addition to documenting a 47% incidence of ES
after syngeneic HSCT, we identified patient age $50
years as a risk factor for developing ES (P 5 .05),
with a possible role for TBI-based conditioning (P 5
.09). Of clinical concern is the finding that patients
with ES had 5-year cumulative incidence of NRM of
21% versus 0% for those without ES (P 5 .06). Al-
though of borderline statistical significance, it raises
concerns that ES may have clinically relevant longer-
term impact. Notably, steroid therapy, despite induc-
ing prompt symptom resolution, did not reduce
NRM risk. In our cohort, 2 of 10 ES patients receiving
steroid therapy and 1 of 5 ES patients not receiving
steroid therapy experienced NRM, an identical 20%
incidence. We therefore suggest that the impact of
ES on NRM should be evaluated in a larger multi-
institutional analysis.
We also note a strikingly higher overall relapse in-
cidence (but not NRM) and impaired survival in
patients with myeloid disorders undergoing syngeneic
HSCT. This is in line with published meta-analyses
indicating overall lack of benefit of autologous trans-
plant as a consolidativemodality inmyeloidmalignan-
cies [17-19]. Considering that tumor contamination is
not an issue with syngeneic grafts, the high relapse
incidence speaks to the importance of the allogeneic
graft-versus-leukemia response in myeloid malignan-
cies, likely dependent on mismatch at minor HLA
loci.In summary, this is the first report on ES in pa-
tients undergoing syngeneic HSCT. We identify ES
as a frequent event after syngeneic HSCT, indicating
the need for a high index of suspicion for this diagno-
sis. Older patient age (and possibly TBI-based condi-
tioning) was a risk factor for ES. The possibility of
increased NRM incidence after syngeneic ES needs
further evaluation.ACKNOWLEDGMENTS
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428 Biol Blood Marrow Transplant 17:421-428, 2011J. Koreth et al.Table 1. Clinical Features of ES Patients during Syngeneic HSCT
No. Age Sex Disease Year Rash* Fever† Pulmonary‡ Hepatic§ Renal¶ CNSt GI** Steroids Notes
1 55 F NHL 1999 YES YES NO YES NO NO YES YES Rash, fever, transaminitis, diarrhea
during engraftment.
2 59 F AA 1998 YES YES YES NO NO NO NO YES Rash, fever, pulmonary infiltrates. Steroids
for diffuse alveolar hemorrhage.
3 34 M NHL 1988 YES YES YES YES YES NO NO YES Fevers, rash, pulmonary infiltrates.
Died on D+41 of ARDS
4 47 F MM 2006 YES YES YES YES NO NO YES YES Rash, fever, hypoxia, hepatic dysfunction,
diarrhea during engraftment.
5 25 M HD 1990 YES YES NO YES NO NO YES NO Fever, rash, diarrhea, hepatic dysfunction.
Rash initially thought antibiotic-related
but persisted.
6 30 F ALL 2003 YES YES NO NO NO NO YES YES Rash, fever, diarrhea. Received course
of steroids for ES vs. GVHD.
7 43 M NHL 1995 YES YES YES NO NO YES YES YES Fever, diffuse rash, pulmonary infiltrates,
diarrhea and intermittent confusion.
8 39 M NHL 1986 YES YES NO YES YES NO YES NO Fever, diarrhea, hepatic/renal dysfunction,
generalized rash during engraftment.
9 48 F MDS 1996 YES YES NO NO YES NO YES YES Fever, rash, diarrhea. Rash initially considered
folliculitis, then ‘GVHD’.
10 59 F MDS 2003 YES YES YES NO NO NO NO YES Diffuse erythematous rash considered
‘GVHD’ vs. ES.
11 60 M NHL 1994 YES YES NO NO YES NO NO NO Persistent diffuse rash and fever, and transient
renal dysfunction during engraftment.
12 57 M MDS 2006 YES YES YES YES NO NO YES YES Fever, rash, profuse diarrhea, hepatic
dysfunction. Initially thought drug
reaction, then ES.
13 54 M NHL 2006 YES YES NO NO YES NO YES YES Fever, diffuse rash, diarrhea and transient
renal dysfunction.
14 53 F AML 2009 YES YES NO YES NO NO YES NO Persistent fevers, diarrhea and new onset
rash during engraftment.
15 37 M HD 2009 YES YES NO YES NO NO YES NO Diffuse rash, fevers, hyperbilirubinemia and
profuse diarrhea peri-engraftment.
N.B.: 1) Weight gain $2.5% baseline was not reliably quantified.
2) Diarrhea is considered an ES criterion by Maiolino et al. [3], and is included for completeness.
*Rash: erythrodermatous rash $25% of body surface area, not attributable to a medication.
**GI: noninfectious diarrhea of at least 2 liquid bowel movements/day without identifiable infection.
†Fever: temperature $100.9 F with no identifiable infectious etiology.
‡Pulmonary: noncardiogenic pulmonary edema; with diffuse pulmonary infiltrates, hypoxia.
§Hepatic: total bilirubin $2 mg/dL or hepatic transaminases $2 normal.
¶Renal: serum creatinine $2 baseline.
tCNS: transient encephalopathy unexplainable by other causes.
